Actinium Pharmaceuticals Announces Acceptance of ATNM-400 Abstract for Presentation at SABCS 2026 Highlighting Activity Across Therapy-Resistant Breast Cancer Models

Stock Information for Telomir Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.